You are here: Industry Insights > Merck

News List

Merck and 10x Genomics launch new option for CRISPR research expresspharma
June 12, 2020
The companies will work together as part of 10x Genomics’ 10x Compatible Partnership Program, a global ecosystem of technologies and solutions that provide customers with the ability to enhance their unique research applications and accelerate discovery.
Junshi, Merck Collaborate on Head, Neck Cancer Treatment in China americanpharmaceuticalreview
June 11, 2020
Junshi Biosciences and Merck announced their collaboration on a clinical trial program designed to investigate the efficacy and safety of anti-PD-1 mAb toripalimab (TUOYI®) in combination with Cetuximab (Erbitux®) ...
Lynparza Recommended for Approval in EU by CHMP for BRCA-Mutated Metastatic Pancreatic Cancer americanpharmaceuticalreview
June 10, 2020
AstraZeneca and Merck announced Lynparza (olaparib) has been recommended for marketing authorization in the European Union (EU) for the 1st-line maintenance treatment of patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer.
Merck’s sNDA for RECARBRIO Wins FDA Approval contractpharma
June 08, 2020
For the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Gram-negative microorganisms.
FDA approves Merck’s antibiotic drug to treat hospital-acquired bacterial pneumonia expresspharma
June 05, 2020
The US Food and Drug Administration approved Recarbrio (a combination of imipenem-cilastatin and relebactam) to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years of age and older.
Junshi Biosciences, Merck Partner on SCCHN Combo Therapy contractpharma
June 02, 2020
To study anti-PD-1 mAb toripalimab (TUOYI) in combination with Cetuximab (Erbitux) in metastatic squamous cell carcinomas of the head and neck in China.
Merck and Ridgeback Bio Collaborate contractpharma
May 28, 2020
Merck and Ridgeback Biotherapeutics LP, a closely held biotechnology company, have entered into a collaboration agreement to develop EIDD-2801.
Merck joins race to develop Covid-19 vaccines and drugs pharmaceutical-technology
May 27, 2020
Merck (MSD) has joined the race to develop vaccines and treatments against Covid-19 with separate agreements with Themis, IAVI and Ridgeback Biotherapeutics.
Merck to Acquire Themis contractpharma
May 27, 2020
Will apply its vaccine development capabilities to SARS-CoV-2 vaccine program originated by Themis and Institut Pasteur.
AstraZeneca-Merck’s Lynparza gets US FDA nod for prostate cancer treatment expresspharma
May 21, 2020
The drug approval by the US regulator is for treating patients with a form of prostate cancer that could not be held back by standard hormone therapy.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 51 52 Next page